Concourse Financial Group Securities, Inc. Ikena Oncology, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$0
Q2 2025

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

100.0%

Previous 100.0%

19 transactions

Quarter	Operation	Price Per share
Q2 2025 Aug 12, 2025	BUY	$1.03 - $1.47 $0 - $0
Q1 2025 May 14, 2025	BUY	$1.28 - $1.69 $0 - $0
Q4 2024 Feb 13, 2025	BUY	$1.53 - $1.76 $0 - $0
Q3 2024 Oct 10, 2024	BUY	$1.6 - $1.85 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$1.24 - $1.82 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$1.27 - $2.0 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$1.33 - $4.4 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$4.09 - $6.43 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$4.09 - $6.43 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$3.5 - $7.31 $0 - $0
Q1 2023 May 15, 2023	BUY	$2.62 - $4.97 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$2.0 - $3.7 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$3.46 - $6.0 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$3.23 - $7.4 $0 - $0
Q1 2022 May 09, 2022	BUY	$5.61 - $13.85 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$10.52 - $16.96 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$9.82 - $15.23 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$13.27 - $26.0 $0 - $0
Q1 2021 May 13, 2021	BUY	$25.6 - $32.0 $0 - $0

Others Institutions Holding IKNA

# of Institutions

Shares Held

32.2M

Call Options Held

Put Options Held

Atlas Venture Life Science Advisors, LLC

5.02M
Shares

$6.93 Million
1.48% of portfolio
Blue Owl Capital Holdings LP New York, NY

4.09M
Shares

$5.65 Million
2.97% of portfolio
Bml Capital Management, LLC Zionsville, IN

4.03M
Shares

$5.56 Million
4.09% of portfolio
Bvf Inc San Francisco, CA

4.01M
Shares

$5.53 Million
0.21% of portfolio
Orbimed Advisors LLC San Diego, CA

3.54M
Shares

$4.88 Million
0.17% of portfolio

View Full List

About Ikena Oncology, Inc.

Ticker IKNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,257,500
Market Cap $50M
Description
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...

More about IKNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account